Literature DB >> 14517844

Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.

Isabelle Viard-Leveugle1, Sylvie Veyrenc, Lars E French, Christian Brambilla, Elisabeth Brambilla.   

Abstract

Fas (CD95) and its ligand FasL signal apoptosis and are involved in tissue homeostasis and the elimination of target cells by cytotoxic T cells. Corruption of this signalling pathway in tumour cells, for example by reduced Fas expression or increased FasL expression, can participate in tumour development and immune escape. The present study has analysed Fas/FasL expression and Fas death signalling function in vivo in lung tumour tissues [57 non-small cell lung carcinomas and 64 neuroendocrine lung tumours including small cell lung carcinoma (SCLC)] in comparison with normal lung tissue, and in vitro in neuroendocrine tumour cell lines in comparison with normal human bronchial epithelial cells. The Fas expression score was markedly decreased compared with normal lung tissue in 90% of the 121 lung tumours and was completely lost in 24%. The Fas staining pattern suggested cytoplasmic Fas expression in tumours, whereas membrane expression was observed in normal lung tissue. Loss of Fas at the cell surface was also shown in vitro by FACS analysis of neuroendocrine tumour cell lines and was concomitant with the resistance of tumour cells to FasL-mediated apoptosis according to in vitro cell viability. The lack of cell surface Fas expression in tumour cell lines resulted from the lack of intracellular Fas protein due to impaired Fas gene transcription. The FasL expression score was also decreased in most non-small cell lung carcinomas compared with normal bronchial cells, whereas 91% of SCLCs had higher expression than normal cells. FasL overexpression was related to advanced tumour stage as well as to a Fas/FasL ratio less than 1. It is concluded that a marked decrease in Fas expression may be part of lung tumourigenesis allowing tumour cells to escape from apoptosis. FasL overexpression in the context of Fas down-regulation in SCLC predicts the ability of SCLC cells to induce paracrine killing of Fas-expressing cytotoxic T cells. In lung tumours, Fas restoration may represent a key, although not unique, step in therapeutic strategies to reconstitute the ability of tumour cells to undergo apoptosis. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517844     DOI: 10.1002/path.1428

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  29 in total

1.  Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

Authors:  Terri B Hunter; Neil J Manimala; Kimberly A Luddy; Tracy Catlin; Scott J Antonia
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

2.  Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.

Authors:  Li-Ning Xu; Sheng-Quan Zou; Jian-Ming Wang
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

3.  FAS-1377 A/G polymorphism in breast cancer: a meta-analysis.

Authors:  Jing Zeng; Yi Fang; Peiyu Li
Journal:  Tumour Biol       Date:  2013-11-02

4.  Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis.

Authors:  Jing Zhu; Lei Lu; Xiang Cheng; Rongkai Xie; Zhengqiong Chen; Youfei Li; Guilan Lin; Jianmei Liu; Ying Yang
Journal:  Tumour Biol       Date:  2014-03-12

5.  Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.

Authors:  X Zhang; X Miao; T Sun; W Tan; S Qu; P Xiong; Y Zhou; D Lin
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

6.  Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions.

Authors:  Na-Hye Myong
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

Review 7.  Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.

Authors:  Kosei Yasumoto; Takeshi Hanagiri; Mitsuhiro Takenoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-13

8.  Pathogenesis of lung cancer signalling pathways: roadmap for therapies.

Authors:  E Brambilla; A Gazdar
Journal:  Eur Respir J       Date:  2009-06       Impact factor: 16.671

9.  Pigment epithelial-derived factor (PEDF)-triggered lung cancer cell apoptosis relies on p53 protein-driven Fas ligand (Fas-L) up-regulation and Fas protein cell surface translocation.

Authors:  Lei Li; Ya-Chao Yao; Shu-Huan Fang; Cai-Qi Ma; Yi Cen; Zu-Min Xu; Zhi-Yu Dai; Cen Li; Shuai Li; Ting Zhang; Hong-Hai Hong; Wei-Wei Qi; Ti Zhou; Chao-Yang Li; Xia Yang; Guo-Quan Gao
Journal:  J Biol Chem       Date:  2014-09-15       Impact factor: 5.157

10.  Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas.

Authors:  Yin Li; Ke-Ping Xu; Dong Jiang; Jun Zhao; Jin-Feng Ge; Shi-Ying Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.